Reyon Pharm Q1 2026: Operating Loss of 6.7B Won, Net Loss and Deteriorating Financial Structure

Consolidated revenue: 36.1B won (vs 36.8B in Q1 2025, -1.9%); operating loss: 6.7B won (vs 3.8B loss, widened); net loss: 10.7B won (vs 0.2B profit, turned to loss)
Debt ratio: 116.8% (FY2025 year-end 111.1%); current ratio: 52% (56%) worsened
Borrowings: 217.9B won (current 122.9B, non-current 95B); interest expense: 3.5B won (vs 3.3B)
Cash: 4.3B won (FY2025 year-end 6.7B); operating cash flow: -2.4B won
No treasury share acquisition/cancellation plan, no dividends
Litigation regarding choline alfoscerate re-evaluation in progress; refund liability of 2.5B won recognized
Equity-method loss from associates: 1.1B won; derivative valuation loss: 0.2B won